FRANCINI, EDOARDO
 Distribuzione geografica
Salva come PNG Salva come JPEG
Continente #
NA - Nord America 5.535
AS - Asia 3.784
EU - Europa 2.970
SA - Sud America 1.067
AF - Africa 108
OC - Oceania 32
Continente sconosciuto - Info sul continente non disponibili 1
Totale 13.497
Salva come PNG Salva come JPEG
Nazione #
US - Stati Uniti d'America 5.436
CN - Cina 1.110
RU - Federazione Russa 1.051
SG - Singapore 883
BR - Brasile 833
VN - Vietnam 618
PL - Polonia 530
IT - Italia 397
KR - Corea 390
HK - Hong Kong 357
IE - Irlanda 276
FI - Finlandia 166
AR - Argentina 117
FR - Francia 115
SE - Svezia 105
BD - Bangladesh 93
GB - Regno Unito 79
JP - Giappone 79
ID - Indonesia 74
DE - Germania 66
DK - Danimarca 58
IN - India 58
CA - Canada 51
EC - Ecuador 43
AU - Australia 31
MX - Messico 28
IQ - Iraq 26
LU - Lussemburgo 25
NG - Nigeria 25
JO - Giordania 19
CL - Cile 17
ZA - Sudafrica 17
ES - Italia 16
NL - Olanda 16
BJ - Benin 15
CO - Colombia 14
CH - Svizzera 12
PE - Perù 12
UA - Ucraina 12
MA - Marocco 11
TR - Turchia 10
PK - Pakistan 9
PY - Paraguay 9
UY - Uruguay 9
UZ - Uzbekistan 9
VE - Venezuela 8
DZ - Algeria 7
EG - Egitto 7
KE - Kenya 7
TN - Tunisia 7
SA - Arabia Saudita 6
AT - Austria 5
BO - Bolivia 5
LT - Lituania 5
PH - Filippine 5
AZ - Azerbaigian 4
IL - Israele 4
KW - Kuwait 4
KZ - Kazakistan 4
LV - Lettonia 4
RS - Serbia 4
TW - Taiwan 4
AE - Emirati Arabi Uniti 3
AL - Albania 3
BE - Belgio 3
BY - Bielorussia 3
CI - Costa d'Avorio 3
CR - Costa Rica 3
DO - Repubblica Dominicana 3
HN - Honduras 3
JM - Giamaica 3
TH - Thailandia 3
BA - Bosnia-Erzegovina 2
CZ - Repubblica Ceca 2
GR - Grecia 2
GT - Guatemala 2
HU - Ungheria 2
KG - Kirghizistan 2
MY - Malesia 2
RO - Romania 2
SK - Slovacchia (Repubblica Slovacca) 2
SN - Senegal 2
SV - El Salvador 2
TT - Trinidad e Tobago 2
BG - Bulgaria 1
BH - Bahrain 1
BW - Botswana 1
CD - Congo 1
CY - Cipro 1
EE - Estonia 1
ET - Etiopia 1
GA - Gabon 1
GD - Grenada 1
HR - Croazia 1
HT - Haiti 1
IR - Iran 1
KH - Cambogia 1
LK - Sri Lanka 1
LY - Libia 1
MD - Moldavia 1
Totale 13.487
Salva come PNG Salva come JPEG
Città #
Santa Clara 1.986
Singapore 683
Warsaw 526
Ashburn 505
Seoul 388
Hefei 376
Fairfield 353
Hong Kong 312
Dublin 271
Ho Chi Minh City 204
Woodbridge 184
Seattle 147
Beijing 139
Helsinki 138
The Dalles 128
Hanoi 122
Dallas 120
Cambridge 118
Wilmington 118
Council Bluffs 115
Houston 103
Altamura 96
Lawrence 96
Los Angeles 95
San Jose 93
Lauterbourg 90
Buffalo 89
New York 86
Moscow 84
Tokyo 79
São Paulo 75
Copenhagen 58
Princeton 51
Florence 46
Kent 43
Jakarta 41
Dong Ket 40
San Diego 38
Haiphong 37
Chandler 36
Rio de Janeiro 35
Clifton 34
Guangzhou 34
Boston 33
Rome 30
Buenos Aires 28
Munich 28
Ann Arbor 27
Melbourne 27
Abuja 25
Da Nang 25
Medford 25
Chicago 24
Curitiba 22
Mumbai 21
Hải Dương 20
Shanghai 20
Guayaquil 19
London 19
Redondo Beach 18
Milan 16
Siena 16
Cotonou 15
Lappeenranta 15
Montreal 15
Quito 15
Biên Hòa 14
Brasília 14
Norwalk 14
Salvador 14
Toronto 14
Belo Horizonte 13
Orem 13
Bengaluru 12
Frankfurt am Main 12
Mexico City 12
Roodt-sur-Syre 12
Turku 12
Denver 11
Ninh Bình 11
Thái Bình 11
Poplar 10
Tianjin 10
Atlanta 9
Baghdad 9
Brooklyn 9
Campinas 9
Falls Church 9
Lima 9
Phoenix 9
Shenzhen 9
Amman 8
Can Tho 8
Chennai 8
Dhaka 8
Montevideo 8
Porto Alegre 8
Recife 8
Tukwila 8
West Jordan 8
Totale 9.268
Salva come PNG Salva come JPEG
Nome #
Cisplatin, Etoposide, and Bevacizumab Regimen Followed by Oral Etoposide and Bevacizumab Maintenance Treatment in Patients With Extensive-Stage Small Cell Lung Cancer: A Single-Institution Experience 296
Capecitabine Plus Oxaliplatin and Bevacizumab, Followed by Maintenance Treatment With Capecitabine and Bevacizumab for Patients Aged > 75 Years With Metastatic Colorectal Cancer 209
CD3+ tumor-infiltrating lymphocytes (TILs) as prognostic in patients (pts) with stage II colon cancer (CC) not treated with adjuvant chemotherapy (ADJ) 206
Is there still a place for docetaxel rechallenge in prostate cancer? 204
Tumor fraction in cell-free DNA as a biomarker in prostate cancer 200
Gemcitabine, oxaliplatin, and capecitabine (GEMOXEL) compared with gemcitabine alone in metastatic pancreatic cancer: a randomized phase II study 196
An exceptional overall survival using bevacizumab beyond progression in a patient with Non-small cell lung cancer 196
Circulating free DNA (cfDNA) as biomarker of taxane resistance in metastatic castration-resistant prostate cancer (mCRPC). 192
Low-Dose Estramustine Phosphate and Concomitant Low-Dose Acetylsalicylic Acid in Heavily Pretreated Patients With Advanced Castration-Resistant Prostate Cancer 188
Effects of abiraterone acetate on chronic kidney disease in 2 patients with metastatic castration-resistant prostate cancer 187
A case of eribulin-induced regression of liposarcoma of the left funiculus in a heavily pretreated patient 183
Clinical impact of volume of disease and time of metastatic disease presentation on patients receiving enzalutamide or abiraterone acetate plus prednisone as first-line therapy for metastatic castration-resistant prostate cancer 180
Sequential treatment with epirubicin, oxaliplatin and 5FU (EOF) followed by docetaxel, oxaliplatin and 5FU (DOF) in patients with advanced gastric or gastroesophageal cancer: a single-institution experience 178
Bone Metastases in Renal Cell Carcinoma: Impact of Immunotherapy on Survival 175
Hyperprogressive disease in advanced cancer patients treated with nivolumab: A case series study 174
Impact of new systemic therapies on overall survival of patients with metastatic castration-resistant prostate cancer in a hospital-based registry 173
Bone targeted therapy and skeletal related events in the era of enzalutamide and abiraterone acetate for castration resistant prostate cancer with bone metastases 173
Five years of stable disease with maintenance therapy using bevacizumab and tamoxifen in a patient with metastatic breast cancer 172
Efficacy and Safety of Regorafenib With 2/1 Schedule for Patients ≥ 75 Years With Metastatic Colorectal Cancer (mCRC) After Failure of 2 Lines of Chemotherapy 170
1204PGOLFIG chemo-immunotherapy in metastatic colorectal cancer (mCRC) patients: A fifteen year retrospective analysis 170
Three-weekly oxaliplatin combined with gemcitabine and capecitabine in the first-line treatment of patients with advanced biliary tract cancer 168
Maintenance treatment with oral cyclophosphamide and bevacizumab in patients with recurrent epithelial ovarian cancer 167
Circulating Cell-Free DNA in Renal Cell Carcinoma: The New Era of Precision Medicine 165
Abiraterone in heavily pretreated patients with metastatic castrate-resistant prostate cancer: final analysis of overall survival 160
Abiraterone in heavily pretreated patients with metastatic castrate-resistant prostate cancer 159
Carboplatin, methotrexate, vinblastine, and epirubicin (M-VECa) as salvage treatment in patients with advanced bladder cancer: a phase II study 158
Clinical outcomes of abiraterone acetate (AA) or enzalutamide (E) as first-line therapy (Rx) for men aged ≥75 with metastatic castration-resistant prostate cancer (mCRPC) according to previous use of docetaxel (D) for metastatic castration-sensitive prostate cancer (mCSPC) in a multicenter international registry: A SPARTACUSS – Meet-URO 26 study 157
Treatment of advanced oesophagogastric cancer with FOLFOX-4 regimen followed by leucovorin/bolus and continuous infusion 5-FU as maintenance chemotherapy in patients aged ≥ 75 years with impaired performance status 157
Time of metastatic disease presentation and volume of disease are prognostic for metastatic hormone sensitive prostate cancer (mHSPC) 156
Differential side effects profile in patients with mCRPC treated with abiraterone or enzalutamide: A meta-analysis of randomized controlled trials 156
Role of chemotherapy in the treatment of metastatic castration-resistant prostate cancer patients who have progressed after abiraterone acetate 153
CEA and CA19.9 as early predictors of progression in advanced/metastatic colorectal cancer patients receiving oxaliplatin-based chemotherapy and bevacizumab 152
Manuale di oncologia medica 151
Feasibility of modified docetaxel, oxaliplatin, capecitabine followed by capecitabine as maintenance chemotherapy as first-line therapy for patients with metastatic gastric or gastroesophageal cancer 150
Coagulation factor X promotes resistance to androgen-deprivation therapy in prostate cancer 149
Doxycycline or minocycline may be a viable treatment option against SARS-CoV-2 148
Sex and adverse events of adjuvant chemotherapy in colon cancer: an analysis of 34,640 patients in the ACCENT database 147
Prostate cancer: Developing novel approaches to castration-sensitive disease 147
Efficacy and safety of docetaxel (D) vs androgen-receptor signaling inhibitors (ARSi) as second-line therapy (Rx) after progression on alternative ARSi as first-line Rx for patients who are elderly (≥75 years old) with metastatic castration-resistant prostate cancer (mCRPC) in a multicenter international database: A SPARTACUSS–Meet-URO 26 study 146
Switch maintenance treatment with oral vinorelbine and bevacizumab after induction chemotherapy with cisplatin, gemcitabine and bevacizumab in patients with advanced non-squamous non-small cell lung cancer: a phase II study 144
Docetaxel Activity in the Era of Life-prolonging Hormonal Therapies for Metastatic Castration-resistant Prostate Cancer 143
Association of concomitant bone resorption inhibitors with overall survival among patients with metastatic castration-resistant prostate cancer and bone metastases receiving abiraterone acetate with prednisone as first-line therapy. 143
GOLFIG Chemo-Immunotherapy in Metastatic Colorectal Cancer Patients. A Critical Review on a Long-Lasting Follow-Up 143
Epirubicin-based compared with docetaxel-based chemotherapy for advanced gastric carcinoma: A systematic review and meta-analysis 142
Bone targeted therapy and skeletal related events in the era of modern therapies for castration resistant prostate cancer with bone metastases 141
Tolerability of cabazitaxel in patients with metastatic castration-resistant prostate cancer progressing after docetaxel and abiraterone acetate: a single-institution experience 141
Hypoxia-Inducible Factor in Renal Cell Carcinoma: From Molecular Insights to Targeted Therapies 141
Circulating-free DNA (cfDNA) as biomarker of taxane resistance in metastatic castration-resistant prostate cancer (mCRPC) 140
Gemcitabine plus nab-paclitaxel followed by maintenance treatment with gemcitabine alone as first-line treatment for older adults with locally advanced or metastatic pancreatic cancer 138
Pathological response and outcome after neoadjuvant chemotherapy with DOC (docetaxel, oxaliplatin, capecitabine) or EOF (epirubicin, oxaliplatin, 5-fluorouracil) for clinical T3-T4 non-metastatic gastric cancer 137
The third line of treatment for metastatic prostate cancer patients: Option or strategy? 136
Safety of sorafenib therapy in elderly adults with advanced hepatocellular carcinoma 133
Extramammary invasive Paget’s disease and apocrine angiomatous hamartoma: an unusual association 133
The diagnostic accuracy of PIK3CA mutations by circulating tumor DNA in breast cancer: an individual patient data meta-analysis 130
Relevance of Gender In the Drug-utilization pattern of Non Small Cell Lung Cancer patients at University Hospital of Siena, Italy (UHS). 130
The prognostic value of CD3+ tumor-infiltrating lymphocytes for stage II colon cancer according to use of adjuvant chemotherapy: A large single-institution cohort study. 130
Targeted Therapies for Prostate Cancer 129
Clinical outcomes of volume of disease on patients receiving enzalutamide versus abiraterone acetate plus prednisone as first-line therapy for metastatic castration-resistant prostate cancer 128
Circulating Cell-Free DNA as Biomarker of Taxane Resistance in Metastatic Castration-Resistant Prostate Cancer. 126
Impact of Different Selection Approaches for Identifying Lynch Syndrome-Related Colorectal Cancer Patients: Unity Is Strength 125
Rechallenge of docetaxel combined with epirubicin given on a weekly schedule in advanced castration-resistant prostate cancer patients previously exposed to docetaxel and abiraterone acetate: a single-institution experience 124
Clinical Potential of Circulating Cell-Free DNA (cfDNA) for Longitudinally Monitoring Clinical Outcomes in the First-Line Setting of Non-Small-Cell Lung Cancer (NSCLC): A Real-World Prospective Study 123
Cell-Free DNA: Unveiling the Future of Cancer Diagnostics and Monitoring 123
Outcomes of First-Line Abiraterone Acetate or Enzalutamide for Older Adults With Metastatic Castration-Resistant Prostate Cancer According to Use of Upfront Docetaxel for Metastatic Castration-Sensitive Prostate Cancer in an International Multicenter Registry: A SPARTACUSS-Meet-URO 26 Study 122
Clinical Outcomes of First-line Abiraterone Acetate or Enzalutamide for Metastatic Castration-resistant Prostate Cancer After Androgen Deprivation Therapy + Docetaxel or ADT Alone for Metastatic Hormone-sensitive Prostate Cancer 122
Efficacy of bone resorption inhibitors (BRI) plus abiraterone acetate plus prednisone (AA) vs. AA alone as first-line therapy for men with castration-resistant prostate cancer (CRPC) and bone metastases (BM) in an international multicenter hospital-based registry 118
How to optimize the sequential use of novel therapeutics in metastatic prostate cancer patients? Response should be found in prostate cancer tissue 114
Outcomes of Prechemotherapy (preCRx) Abiraterone Acetate (AA) or Enzalutamide (E) for Metastatic Castration-Resistant Prostate Cancer (mCRPC) after ADT + Docetaxel (D) or ADT Alone for Metastatic Hormone Sensitive Prostate Cancer (mHSPC) in a Multi-Institution Hospital-based Registry. 113
Specific clonal expansion at disease progression (PD) in solid cancers pinpointed by cell free DNA analysis. 112
Genomic analysis of circulating tumor DNA identifies recurrent molecular features with clinical significance in advanced prostate cancer. 112
Time for a revision on the role of PSA response rate as a surrogate marker for median overall survival in docetaxel-based first-line treatment for patients with metastatic hormone-refractory prostate cancer 112
Clinical outcomes of abiraterone acetate + prednisone (AA) + bone resorption inhibitors (BRI) versus AA alone as first-line therapy for castration-resistant prostate cancer (CRPC) with bone metastases (BM) in an international multicenter database 111
No clear evidence of a clinical benefit of a sequential therapy regimen with abiraterone acetate and enzalutamide 108
PSA response rate as a surrogate marker for median overall survival in docetaxel-based first-line treatments for patients with metastatic castration-resistant prostate cancer: an analysis of 22 trials 107
Outcomes of prechemotherapy (pCHT) abiraterone (AA) or enzalutamide (E) for metastatic castration-resistant prostate cancer (mCRPC) after androgen deprivation therapy (ADT) plus docetaxel (D) or ADT alone for metastatic hormone sensitive prostate cancer (mHSPC) in a hospital-based registry 103
Intensification Approaches and Treatment Sequencing in Metastatic Castration-resistant Prostate Cancer: A Systematic Review 103
The role of doxorubicin and epirubicin in the treatment of patients with metastatic hormone-refractory prostate cancer 101
Capecitabine as third-line treatment in patients with metastatic renal cell carcinoma after failing immunotherapy 101
Using Linked Administrative And Pathology Database To Describe Treatment Patterns Of Non-small-cell Lung Cancer Patients At The Azienda Ospedaliera Universitaria Senese 95
Significance of PD-L1 in Metastatic Urothelial Carcinoma Treated With Immune Checkpoint Inhibitors: A Systematic Review and Meta-Analysis 94
Docetaxel Versus Androgen-Receptor Signaling Inhibitors (ARSI) as Second-Line Therapy After Failure of First-Line Alternative ARSI for the Elderly ≥ 75 Years Old With Metastatic Castration-Resistant Prostate Cancer (mCRPC): A SPARTACUSS-Meet-URO 26 Real-World Study 94
Prior therapy and volume of disease are prognostic for metastatic hormone sensitive prostate cancer (mHSPC) in a hospital-based database 92
Bevacizumab and Weekly Docetaxel in Patients with Metastatic Castrate-Resistant Prostate Cancer Previously Exposed to Docetaxel 90
Clinical outcomes of sunitinib (Su) for patients (pts) with desmoid tumors (DT) 90
FOLFOX-4 Stop and Go and Capecitabine Maintenance Chemotherapy in the Treatment of Metastatic Colorectal Cancer 88
Androgen Blockade and Salvage ­Radiation Therapy in Prostate Cancer: Cautious Optimism Amid Unanswered Questions 86
Impact of new systemic therapies on overall survival (OS) of patients (pts) with metastatic castration resistant prostate cancer (mCRPC) in a hospital-based registry 84
GOLFIG chemo-immunotherapy in metastatic colorectal cancer (mCRC) patients: A fifteen year retrospective analysis 83
Thymidine phosphorylase expression in metastatic sites is predictive for response in patients with colorectal cancer treated with continuous oral capecitabine and biweekly oxaliplatin 82
Effects of intravenous zoledronic acid and oral ibandronate on early changes in markers of bone turnover in patients with bone metastases from non-small cell lung cancer 81
Oral Metronomic Chemo-Hormonal-Therapy of Metastatic Breast Cancer with Cyclophosphamide and Megestrol Acetate 78
Docetaxel and epirubicin compared with docetaxel and prednisone in advanced castrate-resistant prostate cancer: a randomised phase II study 78
Reduced Dose of Abiraterone Acetate with Concomitant Low-dose Prednisone in the Treatment of ≥ 85 Year-old Patients with Advanced Castrate-resistant Prostate Cancer 78
Continuous oral capecitabine at fixed dose in patients older than 75 years with metastatic colorectal and gastric cancer: a study of the Multidisciplinary Oncology Group on Gastrointestinal Tumors 71
Osteonecrosis of the jaw in patients with cancer who received zoledronic acid and bevacizumab 71
Weekly high‐dose calcitriol and docetaxel in patients with metastatic hormone‐refractory prostate cancer previously exposed to docetaxel 70
Immunity Feedback and Clinical Outcome in Colon Cancer Patients Undergoing Chemoimmunotherapy with Gemcitabine + FOLFOX followed by Subcutaneous Granulocyte Macrophage Colony-Stimulating Factor and Aldesleukin (GOLFIG-1 Trial) 65
Exemestane after tamoxifen as adjuvant hormonal therapy in postmenopausal women with breast cancer: effects on body composition and lipids 64
Efficacy and safety analysis of once per cycle pegfilgrastim and daily lenograstim in patients with breast cancer receiving adjuvant myelosuppressive chemotherapy FEC 100: a pilot study 64
Tolerability of single-agent sorafenib in the treatment of elderly patients with hepatocellular carcinoma (HCC) 63
Totale 13.411
Salva come PNG Salva come JPEG
Categoria #
all - tutte 35.044
article - articoli 0
book - libri 0
conference - conferenze 0
curatela - curatele 0
other - altro 0
patent - brevetti 0
selected - selezionate 0
volume - volumi 0
Totale 35.044
Salva come PNG Salva come JPEG


Totale Lug Ago Sett Ott Nov Dic Gen Feb Mar Apr Mag Giu
2020/2021120 0 0 0 0 0 0 0 0 0 0 71 49
2021/2022363 5 5 21 24 4 41 45 22 15 17 63 101
2022/2023631 77 203 37 34 4 116 95 8 43 0 8 6
2023/2024519 8 18 53 48 78 97 10 69 21 46 42 29
2024/20253.998 130 265 156 411 1.314 1.054 68 96 105 73 119 207
2025/20266.398 369 1.034 1.067 1.304 582 194 631 319 319 317 262 0
Totale 13.655